Sidney Farber

(redirected from Farber disease)
Also found in: Medical, Wikipedia.

Farber, Sidney

(1903–73) oncologist; born in Buffalo, N.Y. He began as a pathologist at the Children's Hospital in Boston and taught at Harvard (1929). His life's work revolved around cancer therapy, research, and patient care. In 1947 he founded the Children's Cancer Research Foundation (now, in his honor, the Dana-Farber Cancer Center) and achieved the first remissions in childhood leukemia by using chemotherapy.
References in periodicals archive ?
The company is also preparing to initiate a clinical trial of RVT-801, an investigational enzyme replacement therapy for the treatment of Farber disease.
M2 EQUITYBITES-March 22, 2019-Enzyvant wins US FDA's Fast Track and Rare Pediatric Disease designations for Farber Disease Enzyme Replacement Therapy, RVT-801
Global Banking News-March 22, 2019-Enzyvant wins US FDA's Fast Track and Rare Pediatric Disease designations for Farber Disease Enzyme Replacement Therapy, RVT-801
Enzyvant, a subsidiary of Roivant Sciences, has selected Avid Bioservices as the commercial drug substance manufacturer for RVT801, its recombinant human acid ceramidase enzyme replacement therapy being developed as a potential treatment for Farber disease. Successful technology transfer and clinical manufacturing have been underway since mid-2017 and Avid will complete process characterization and optimization followed by process validation in support of Enzyvant7s ongoing development and regulatory activities for RVT-801, which include the initiation of a first-in-human clinical study.
The main histologic differential diagnoses are other nephropathies with foamy podocytes, such as lysosomal inhibitor toxicity and other renal lipidoses (GM1 gangliosidosis, I-cell disease, Hurler syndrome, Niemann-Pick disease, Farber disease, and infantile nephrosialidosis).
Sands, "Farber disease: understanding a fatal childhood disorder and dissecting ceramide biology," EMBO Molecular Medicine, vol.
M2 PHARMA-March 22, 2019-Enzyvant wins US FDA's Fast Track and Rare Pediatric Disease designations for Farber Disease Enzyme Replacement Therapy, RVT-801